Elevio Group is pleased to announce its participation at ISPOR Europe 2025, where our partner Jessica Weddle will moderate a panel session dedicated to one of the most dynamic and strategically important topics in today’s Market Access landscape:
the evolution of access frameworks for next-generation multi-indication / Immunology therapies
As scientific progress in I&I continues to accelerate—with increasingly durable treatments, new mechanisms of action, and expanding indication strategies—the traditional access and reimbursement paradigms are under pressure. This session will bring together senior leaders from industry and HTA to explore how policies, evidence requirements, and payer expectations must evolve to ensure sustainable access for patients.
Panel Overview
The session, titled “Rethinking Access Frameworks for the Next Generation of Multi-Indication / Immunology Therapies,” will address:
- The growing complexity of multi-indication development strategies
- New clinical concepts such as remission, off-treatment durability, and phenotype-driven segmentation
- Implications for HTA decision-making and cross-country reimbursement models
- The need for adaptive, forward-looking frameworks to capture the full value of innovative I&I assets
This discussion is directly aligned with Elevio Group’s expertise in Market Access, pricing frameworks, and advanced forecasting for multi-indication assets through our ElevioSight platform.
Practical Information
Date: Wednesday, 12 November 2025
Time: 08:00 AM
Event: ISPOR Europe 2025
Session Type: Panel Discussion (Issue Panel)
We look forward to exchanging with colleagues, partners, and industry leaders during the conference.
To schedule a meeting with the Elevio Group team at ISPOR Europe 2025, please contact us at info@eleviogroup.com.
